Miller to Helm Industry Leading Amorphous Solid Dispersion Science Team
GEORGETOWN, Texas, July 14, 2021--(BUSINESS WIRE)--DisperSol Technologies LLC announced today that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.
"Dave is one of the world’s leading formulation scientists and, in my view, the pre-eminent expert in drug solubility and absorption enhancement," said Dr. Edward Rudnic, CEO of DisperSol Technologies. "Dave co-invented DisperSol’s proprietary technology platform, KinetiSol, and has built and trained one of the top amorphous solid dispersion science teams in the pharmaceutical industry. Over the last decade, his team has worked on many of the hardest formulation problems in pharmaceuticals and managed an unprecedented success rate on those problems of over 90%. It is my privilege to announce his promotion to Chief Scientific Officer."
"As DisperSol’s Chief Scientific Officer, I look forward to continuing to work on and solve some of the most intractable challenges in oral small molecule development," said Dave Miller. "I appreciate the company’s faith in me and my team and we will work hard to prove it is well placed."
Prior to joining DisperSol, Dr. Miller was a Senior Principal Scientist in the Pharmaceutical and Analytical Research and Development department at Hoffmann-La Roche, Inc. in Nutley, NJ. Dr. Miller specializes in formulation and processing technologies for improving oral bioavailability of insoluble small molecules. He has applied his expertise toward advancing numerous drug candidates through all stages of development from early discovery to line extension. He has published 42 research articles in peer-reviewed journals, authored 7 book chapters, and is co-editor of the First, Second, and Third Editions of the textbook, Formulating Poorly Water-Soluble Drugs. He has 8 granted patents in the United States and numerous pending applications. Dr. Miller holds a B.S. in Chemical Engineering and a Ph.D. in Pharmaceutics from the University of Texas at Austin.
About DisperSol Technologies
DisperSol is a clinical-stage drug development company focused on developing new treatments for patients utilizing its proprietary KinetiSol® technology platform. KinetiSol has proven capable of creating novel therapeutics from poorly bioavailable drugs to deliver unique clinical benefits to patients. The platform enables a drug development path forward to patients when other options fail to make a difference. DisperSol’s active programs include, DST-0509 about to enter Phase 3 for iron overload disorder, DST-2970 in Phase 2 for refractory metastatic prostate cancer and DST-8294 for treatment of clotting disorders. Additional earlier-stage programs include, DST-0058 and DST-5407 for idiopathic pulmonary fibrosis and non-squamous non-small cell lung cancer, respectively.
For more information, visit www.dispersoltech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005772/en/
Vice President, Business Development & Marketing